NodThera has reported positive Phase I study readouts of its NLRP3 inflammasome inhibitors, NT-0796 and NT-0249, to potentially treat central nervous system (CNS) and peripheral inflammatory diseases. 

An orally bioavailable chemotype, NT-0796 is a brain penetrant inhibitor of NLRP3. 

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The Phase I trial of NT-0796 has concluded and established the compound’s brain penetration, with exceptional pharmacokinetic (PK) and pharmacodynamic (PD) profiles.

Exposures of the compound, as well as its bioactive metabolite NDT-19795, were observed to rise linearly with doses.

NT-0796 was also found to be safe and well tolerated, without any drug-associated liver function test (LFT) abnormalities reported.

NT-0249 is a peripherally restricted inhibitor of the NLRP3 inflammasome. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Dosing with NT-0249 in the Phase I single ascending dose cohorts have also concluded, validating an excellent PK/PD profile, as well as the possibility for once-daily dosing. 

PK was validated as a reduced clinical dose of the compound for efficacy.

NT-0249 was reported to be safe and well tolerated, with proportional rises in drug exposure on increasing dosage. 

The combined data backs the further development and clinical assessment of these candidates for various CNS and peripheral inflammatory ailments.

NodThera CEO Adam Keeney said: “We are delighted that NT-0796 continues to demonstrate an exceptional and differentiated clinical profile. 

“Neurological and neurodegenerative diseases are a significant and growing burden to patients and society. 

“This is the first clinical demonstration of a brain penetrant inhibitor of the NLRP3 inflammasome, which represents a major milestone for addressing this urgent medical challenge.”

A clinical-stage biotechnology firm, NodThera focuses on the development of a new class of NLRP3 inflammasome inhibitors to treat chronic inflammation-driven ailments.